United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
319.85
-3.09 (-0.96%)
Mar 18, 2025, 12:53 PM EDT - Market open

Company Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.

It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.

United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation
United Therapeutics logo
Country United States
Founded 1996
IPO Date Jun 17, 1999
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Martine Rothblatt

Contact Details

Address:
1000 Spring Street
Silver Spring, Maryland 20910
United States
Phone 301 608 9292
Website unither.com

Stock Details

Ticker Symbol UTHR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001082554
CUSIP Number 91307C102
ISIN Number US91307C1027
Employer ID 52-1984749
SIC Code 2834

Key Executives

Name Position
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman and Chief Executive Officer
Michael I. Benkowitz President and Chief Operating Officer
James C. Edgemond Chief Financial Officer and Treasurer
Paul A. Mahon J.D. Executive Vice President, General Counsel and Corporate Secretary
Dewey Steadman C.F.A. Head of Investor Relations
Holly Hobson Associate Vice President of Human Resources
Kevin T. Gray Senior Vice President of Strategic Operations and Logistics
Patrick Poisson Executive Vice President of Technical Operations
Dr. Leigh Peterson Executive Vice President of Product Development and Xenotransplantation
Gil Golden Senior Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 10, 2025 144 Filing
Feb 28, 2025 144 Filing
Feb 28, 2025 144 Filing
Feb 26, 2025 8-K Current Report
Feb 26, 2025 10-K Annual Report
Feb 10, 2025 144 Filing
Feb 10, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 SCHEDULE 13G Filing
Jan 13, 2025 144 Filing
Jan 13, 2025 8-K Current Report